Science knows no boundaries. Researchers are collaborating across borders to share information and co-develop biotech tools to use in the fight against the coronavirus.  

Notable Collaborations Include: 

• Pfizer, a US-based pharmaceutical company, is working with BioNTech, a German company researching new kinds of immunotherapy treatments. 

• Abcellera, a Canadian company and Eli Lilly have partnered to identify more than 500 human antibodies as possible candidates for development as a COVID-19 treatment.
 

Combatting this pandemic calls for global collaboration that supports the research and development of vaccines and treatments.   

Notable Efforts Include:  

• Access to COVID-19 Tools (ACT) Accelerator Act: A global coordination program launched to accelerate the development and availability of new COVID-19 tools. Key partners include the European Commission, Bill and Melinda Gates Foundation, Wellcome TrustCoalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization and others.  

• Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership: Launched by the Foundation for the NIH as a public-private partnership to review the R&D landscape and assist companies with promising projects. 

• Gates Foundation Therapeutics Accelerator: The Gates Foundation, in partnership with Wellcome Trust and Mastercard, launched this funding opportunity for R&D of COVID-19 therapeutics.